Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 17/20 | 0.91 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.60 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.60 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6554701 | 1.00 | GRIA4 (0.91) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL6936166 | 1.00 | GRIA4 (0.91) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL5877988 | 0.95 | GRIA4 (1.00) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL6565117 | 0.91 | GRIA4 (0.77) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL5877671 | 0.89 | GRIA4 (0.73) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL13255761 | 0.86 | GRIA4 (0.87) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL5992693 | 0.86 | GRIA4 (0.87) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL6554699 | 0.85 | GRIA4 (0.67) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL5878987 | 0.84 | GRIA4 (0.90) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL6563414 | 0.84 | GRIA4 (0.67) | GRIA4GRIA2GRIA1GRIA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7135487-B2 | such as N-2-(4-Bromophenyl)propyl methanesulfonamide; sulfonamidation of the amine; glutamate receptor potentiators | ELI LILLY AND COMPANY (US) | 2006-11-14 | — | — | US | disclosed |
| US-20060030599-A1 | SULPHONAMIDE DERIVATIVES | ARNOLD MACKLIN B | 2006-02-09 | — | — | US | disclosed |
| EP-1528055-A2 | Sulphonamide Derivatives | Eli Lilly & Company (US) | 2005-05-04 | — | — | EP | disclosed |
| EP-0860428-B1 | Sulphonamide derivatives | LILLY CO ELI (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040235957-A1 | Use of sulfonamide derivatives as pharmaceuticals compounds | BLEAKMAN DAVID (US) | 2004-11-25 | — | — | US | disclosed |
| US-6803484-B2 | Sulfonamide derivatives | ELI LILLY AND COMPANY | 2004-10-12 | — | — | US | disclosed |
| US-20040143020-A1 | Sulfonamide derivatives | AIKINS JAMES ABRAHAM (US) | 2004-07-22 | — | — | US | disclosed |
| EP-1438036-A2 | USE OF SULFONAMIDE DERIVATIVES AS PHARMACEUTICALS COMPOUNDS | ELI LILLY AND COMPANY (US) | 2004-07-21 | — | — | EP | disclosed |
| US-6720357-B2 | TREATMENT OF CONDITIONS ASSOCIATED WITH GLUTAMATE HYPOFUNCTION, SUCH AS PSYCHIATRIC AND NEUROLOGICAL DISORDERS; N-2-(4-N-(3,5-DIFLUOROBENZAMIDO)PHENYL)PROPYL-2-PROPANESULFONAMIDE | ELI LILLY AND COMPANY | 2004-04-13 | — | — | US | disclosed |
| US-20040054009-A1 | (BIS)sulfonamide derivatives | KNOBELSDORF JAMES ALLEN (US) | 2004-03-18 | — | — | US | disclosed |
| US-6525099-B1 | Potentiating glutamate receptor function; psychiatric and neurological disorders | ELI LILLY AND COMPANY | 2003-02-25 | — | — | US | disclosed |
| WO-2002089848-A2 | USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TYPE 2 DIABETES | ELI LILLY AND COMPANY (US) | 2002-11-14 | — | — | WO | disclosed |
| US-20020002158-A1 | Sulphonamide derivatives | ARNOLD MACKLIN B (US) | 2002-01-03 | — | — | US | disclosed |
| WO-2001089510-A2 | USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE TREATMENT OF OBESITY | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001090056-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
| US-6303816-B1 | Sulphonamide derivatives | ELI LILLY AND COMPANY | 2001-10-16 | — | — | US | disclosed |
| EP-0994110-A1 | Sulphonamide derivatives | ELI LILLY AND COMPANY (US) | 2000-04-19 | — | — | EP | disclosed |
| WO-2000006537-A1 | N-SUBSTITUTED SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| EP-0860428-A2 | Sulphonamide derivatives | ELI LILLY AND COMPANY (US) | 1998-08-26 | — | — | EP | disclosed |
| WO-1998033496-A1 | SULPHONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1998-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030599-A1 | SULPHONAMIDE DERIVATIVES | GRIN2C, GLRA2, GLRA1 | GRIA4 19/4885GRIA2 18/4885GRIA1 39/4885 |
| US-20020002158-A1 | Sulphonamide derivatives | GRIN2C, GRM1, GRM3 | GRIA4 20/4885GRIA2 27/4885GRIA1 17/4885 |
| US-20040054009-A1 | (BIS)sulfonamide derivatives | GRIN2A, GRIN2B, GABRE | GRIA4 14/4885GRIA2 9/4885GRIA1 15/4885 |
| US-20040143020-A1 | Sulfonamide derivatives | GRIN2A, GRIN2B, SLC1A2 | GRIA4 13/4885GRIA2 10/4885GRIA1 16/4885 |
| US-20040235957-A1 | Use of sulfonamide derivatives as pharmaceuticals compounds | GABRE, SCN2A, SCN1A | GRIA4 212/4885GRIA2 176/4885GRIA1 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.